Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
2.
Transplantation ; 72(6): 1050-5, 2001 Sep 27.
Article in English | MEDLINE | ID: mdl-11579299

ABSTRACT

BACKGROUND: The aim of this study was to compare the efficacy and safety of induction treatment with antithymocyte globulins (ATG) followed by tacrolimus therapy with immediate tacrolimus therapy in renal transplant recipients. METHODS: This 12-month, open, prospective study was conducted in 15 centers in France and 1 center in Belgium; 309 patients were randomized to receive either induction therapy with ATG (n=151) followed by initiation of tacrolimus on day 9 or immediate tacrolimus-based triple therapy (n=158). In both study arms, the initial daily tacrolimus dose was 0.2 mg/kg. Steroid boluses were given in the first 2 days and tapered thereafter from 20 mg/day to 5 mg/day. Azathioprine was administered at 1-2 mg/kg per day. RESULTS: At month 12, biopsy-confirmed acute rejections were reported for 15.2% (induction) and 30.4% (noninduction) of patients (P=0.001). The incidence of steroid-sensitive acute rejections was 7.9% (induction) and 22.2% (noninduction)(P=0.001). Steroid-resistant acute rejections were reported for 8.6% (induction) and 8.9% (noninduction) of patients. A total of nine patients died. Patient survival and graft survival at month 12 was similar in both treatment groups (97.4% vs. 96.8% and 92.1% vs. 91.1%, respectively). Statistically significant differences in the incidence of adverse events were found for cytomegalovirus (CMV) infection (induction, 32.5% vs. noninduction, 19.0%, P=0.009), leukopenia (37.3% vs. 9.5%, P<0.001), fever (25.2% vs. 10.1%, P=0.001), herpes simplex (17.9% vs. 5.7%, P=0.001), and thrombocytopenia (11.3% vs. 3.2%, P=0.007). In the induction group, serum sickness was observed in 10.6% of patients. The incidence of new onset diabetes mellitus was 3.4% (induction) and 4.5% (noninduction). CONCLUSION: Low incidences of acute rejection were found in both treatment arms. Induction treatment with ATG has the advantage of a lower incidence of acute rejection, but it significantly increases adverse events, particularly CMV infection.


Subject(s)
Antilymphocyte Serum/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Tacrolimus/therapeutic use , Adult , Drug Resistance , Female , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Graft Rejection/prevention & control , Graft Survival , Humans , Immunosuppressive Agents/adverse effects , Incidence , Kidney/physiopathology , Kidney Transplantation/mortality , Male , Middle Aged , Retrospective Studies , Steroids/therapeutic use , Tacrolimus/adverse effects
3.
J Infect Dis ; 184(5): 533-41, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11494158

ABSTRACT

gammadelta T cells undergo massive expansion in the peripheral blood of renal transplant recipients who are infected with cytomegalovirus (CMV). In a 3-year prospective study, the relationship between the evolution of CMV infection and the kinetics of gammadelta T cell amplification was followed for 10 months after transplantation. Patients with late gammadelta T cell expansion (>/=45 days) had significantly longer (P<.0001) and higher (P<.0003) pp65 antigenemia and more-symptomatic CMV disease than did patients with early expansion. Analysis of data for each patient showed that gammadelta T cell expansion is concomitant with the resolution of CMV infection and disease, regardless of the CMV serologic status of donor and recipient before transplantation. These observations point to gammadelta T cell percentage determination as a new, rapid, and reliable prognosis factor to predict the resolution of CMV infection and strongly suggest that gammadelta T cells play a protective role against CMV infection.


Subject(s)
Cytomegalovirus Infections/immunology , Kidney Transplantation/adverse effects , Phosphoproteins/immunology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocytes/immunology , Viral Matrix Proteins/immunology , Adult , Aged , Cytomegalovirus/immunology , Cytomegalovirus Infections/physiopathology , Female , Flow Cytometry , Humans , Lymphocyte Activation , Lymphocyte Count , Male , Middle Aged , Prospective Studies
4.
J Immunol Methods ; 256(1-2): 77-87, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11516757

ABSTRACT

The concentration of the immunosuppressive drugs cyclosporine A (CSA) and FK506 in biological fluids is routinely determined by antibody-based assays, which for several reasons do not give accurate information on the actual level of immunosuppression in the patient. To alleviate this problem, we developed a functional reporter gene assay which uses the enhancer fragment of the interleukin-2 promoter region driving the expression of the green fluorescent protein (GFP). This construct was stably transfected in the Jurkat human T lymphoblastoid cell line. Upon stimulation of the cell recipient, the GFP was produced and evaluated by flow cytometry. Immunosuppressants acting via inhibition of interleukin-2 synthesis, such as CSA or FK506, inhibited the production of GFP in a dose-dependent manner. This assay can be performed within a working day with a good reproducibility and was more sensitive than the antibody-based assays, since its detection limit was as low as 10 ng/ml for CSA and 0.5 ng/ml for FK506. We used it for the follow up of drug level present in the blood of transplanted patients, and compared the results with those obtained with the antibody-based assay routinely carried out in our hospital. The conclusions suggest that this assay is a valuable alternative to the presently available assays for the measurement of the immunosuppressive activity found in body fluids.


Subject(s)
Cyclosporine/blood , Flow Cytometry/methods , Immunosuppressive Agents/blood , Interleukin-2/genetics , Luminescent Proteins/genetics , Tacrolimus/blood , Antibodies, Monoclonal/immunology , Dose-Response Relationship, Drug , Genes, Reporter , Glucocorticoids/pharmacology , Green Fluorescent Proteins , Humans , Jurkat Cells , Kidney Transplantation , Luminescent Proteins/metabolism , Methylprednisolone/pharmacology , Promoter Regions, Genetic , Recombinant Fusion Proteins/metabolism
5.
Clin Transplant ; 15(3): 199-207, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11389711

ABSTRACT

The aim of this study was to analyze the status of patients with a successful long-term (> or =20 yr) kidney graft. Nineteen (8.1%) of the 234 recipients who received a cadaveric kidney transplant between 1968 and 1978 in our center are still alive 21.7+/-1.6 yr (mean+/-standard error of the mean) later with a functioning allograft. Function, including measurement of the renal functional reserve (RFR), histological status, and morbidity were evaluated. Fourteen patients agreed to participate in this study. Their current immunosuppressive regimens combined prednisone (P)+azathioprine (AZA) (n=9), P+AZA+cyclosporine (CsA) (n=3) or P+CsA (n=2). Although they described their quality of life as good, 10 patients had mild hypertension, 5 developed 10 malignancies (9 cutaneous), 5 had replicative hepatitis, 8 had osteopenia, and 6 had cataracts, but none had diabetes mellitus. Proteinuria was detected in 6 patients, but was always less than 1 g/d. Mean serum creatinine was 1.28+/-0.28 mg/dL and glomerular filtration rate was 54.5+/-5.3 mL/min/1.73 m2. RFR was present for 4 patients with a mean value of +14.8+/-1.9 mL/min. Their functional status was not correlated with the histological lesions observed in concomitant transplant biopsies. Kidney grafts are able to function well even more than 20 yr post-transplantation, with some having a RFR whose significance remains unknown. Morbidity is of minor clinical severity, but could be further reduced with optimized management. Moreover, transplantation is much less costly than hemodialysis.


Subject(s)
Kidney Transplantation , Adult , Cadaver , Female , Follow-Up Studies , Graft Survival/physiology , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/physiology , Male , Morbidity , Postoperative Complications/epidemiology , Quality of Life , Time Factors
9.
Cytokine ; 12(3): 265-71, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10704254

ABSTRACT

Leukaemia inhibitory factor (LIF) is a pleiotropic cytokine that is particularly involved in nephrogenesis and repair of the extracellular matrix. Transgenic mice overexpressing LIF have mesangial proliferative glomerulonephritis. Also, during local inflammatory reactions, such as kidney graft rejection or urinary tract infections, urinary LIF excretion is enhanced. The aim of the study therefore was to study LIF production by normal and inflammatory diseased kidneys (glomerulonephritis or graft rejection), maintained in short cultures. To determine the responsibility of the kidney itself in LIF synthesis, we measured LIF secretion into the culture supernatants of human mesangial or renal tubular epithelial cells. Fragments from diseased kidneys, whether grafts or not, released more LIF than normal human kidney fragments, mesangial or renal tubular epithelial cells. However, LIF production was delayed in renal transplants compared to glomerulonephritic samples taken from untreated patients. In every case, LIF production was enhanced by interleukin 1beta (IL-1beta) and inhibited by IL-4 or dexamethasone, except in two severe rejection episodes. So, LIF appeared to respond to pro- and anti-inflammatory stimuli, in vitro and in vivo. Considering its biological effects, LIF could play a role in inflammatory renal diseases.


Subject(s)
Growth Inhibitors/biosynthesis , Interleukin-6 , Kidney Diseases/metabolism , Kidney/metabolism , Lymphokines/biosynthesis , Animals , Biopsy , Cells, Cultured , Glomerular Mesangium/cytology , Glomerular Mesangium/metabolism , Growth Inhibitors/metabolism , Humans , Interleukin-1/biosynthesis , Interleukin-1/metabolism , Kidney Diseases/pathology , Kidney Tubules/cytology , Kidney Tubules/metabolism , Leukemia Inhibitory Factor , Lymphokines/metabolism , Mice , Middle Aged
11.
Kidney Int ; 56(2): 642-9, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10432404

ABSTRACT

BACKGROUND: Chronic uremia is responsible for secondary hyperparathyroidism (HPT II). Parathyroid secretion usually tends to normalize after kidney transplantation (KT), but the parameters of the reversibility of HPT II remain poorly defined, particularly the intrinsic mechanisms underlying the improvement of parathyroid function. METHODS: The kinetic functional parameters of the ionized calcium (iCa)/parathormone (PTH) relationship curve were studied in 11 patients with mild to moderate HPT II one and six months after successful KT. Hypercalcemia and hypocalcemia were induced, respectively, by CaCl2 and Na2-ethylenediaminetetraacetic acid (Na2-EDTA) infusions. RESULTS: The mean glomerular filtration rate remained stable during follow-up. Basal PTH decreased from 195 +/- 54 pg/ml before KT to 70 +/- 12 pg/ml six months later (P < 0. 005). During the tests, mean PTH levels decreased significantly between the two measured times for all iCa levels, indicating an improved parathyroid function. An analysis of the kinetic parameters of the curves showed significant decreases of the mean maximal and minimal PTH levels, respectively, from 340 +/- 91 to 220 +/- 30 pg/ml (P = 0.03) and from 25 +/- 6 to 15 +/- 5 pg/ml (P = 0.005). On the other hand, no change was noted in the parathyroid-cell calcium-sensitivity parameters (slope, set point) assessed using two different approaches, either the entire curve or the limited calcium-mediated suppression curve. CONCLUSION: Improvement of the parathyroid function between the first and sixth months post-KT seems mainly attributable to a reduction of the parathyroid functional mass.


Subject(s)
Kidney Transplantation , Parathyroid Glands/pathology , Postoperative Complications/pathology , Adult , Bone and Bones/metabolism , Calcium/blood , Calcium Chloride/administration & dosage , Edetic Acid/administration & dosage , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/pathology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/pathology , Kidney Failure, Chronic/surgery , Male , Middle Aged , Parathyroid Glands/metabolism , Parathyroid Hormone/blood , Parathyroid Hormone/metabolism
12.
J Clin Invest ; 103(10): 1437-49, 1999 May 15.
Article in English | MEDLINE | ID: mdl-10330426

ABSTRACT

In normal individuals, gammadelta T cells account for less than 6% of total peripheral T lymphocytes and mainly express T-cell receptor (TCR) Vdelta2-Vgamma9 chains. We have previously observed a dramatic expansion of gammadelta T cells in the peripheral blood of renal allograft recipients only when they developed cytomegalovirus (CMV) infection. This increase was long lasting (more than 1 year), was associated with an activation of gammadelta T cells, and concerned only Vdelta1 or Vdelta3 T-cell subpopulations. Analysis of gammadelta TCR junctional diversity revealed that CMV infection in these patients was accompanied by (a) a marked restriction of CDR3 size distribution in Vdelta3 and, to a lesser extent, in Vdelta1 chains; and (b) a selective expansion of Vdelta1 cells bearing recurrent junctional amino acid motifs. These features are highly suggestive of an in vivo antigen-driven selection of gammadelta T-cell subsets during the course of CMV infection. Furthermore, Vdelta1 and Vdelta3 T cells from CMV-infected kidney recipients were able to proliferate in vitro in the presence of free CMV or CMV-infected fibroblast lysates but not uninfected or other herpes virus-infected fibroblast lysates. This in vitro expansion was inhibited by anti-gammadelta TCR mAb's. These findings suggest that a population of gammadelta T cells might play an important role in the immune response of immunosuppressed patients to CMV infection.


Subject(s)
Cytomegalovirus/immunology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocyte Subsets/immunology , Adolescent , Adult , Amino Acid Sequence , Base Sequence , Child , Cytomegalovirus Infections/etiology , Cytomegalovirus Infections/immunology , DNA Primers/genetics , Female , Humans , In Vitro Techniques , Kidney Transplantation/adverse effects , Kidney Transplantation/immunology , Lymphocyte Activation , Male , Middle Aged , Molecular Sequence Data , Receptors, Antigen, T-Cell, gamma-delta/genetics , Time Factors
14.
J Nucl Med ; 40(3): 412-7, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10086704

ABSTRACT

UNLABELLED: The aims of this study were to show the value of captopril renal scintigraphy for detecting a renovascular cause in hypertensive patients with renal failure and to assess the ability to predict the beneficial effect of revascularization on renal function. METHODS: Thirty-eight patients with renal failure (mean glomerular filtration rate = 35 mL/min) underwent renal scintigraphy after injection of 99mTc-mercaptoacetyltriglycine. Baseline scintigraphy was performed, and the test was repeated 24 h later after oral administration of 50 mg captopril given 60 min before the test. RESULTS: In 5 of 6 patients with a renovascular cause for renal failure, and 2 of 3 patients with a probable arterial pathology, scintigraphy had a high probability. The result was indeterminate in the other 2 patients. In 5 of 11 patients with negative arteriography and 14 of 18 patients with probable absence of renovascular pathology, we found a low probability of functional renal artery stenosis. Six revascularization procedures were performed and were predictive of a beneficial effect in 5 patients. Time of peak activity was an effective predictor in each case. CONCLUSION: In hypertensive patients with renal failure, captopril renal scintigraphy can detect hemodynamic dysfunction downstream from a renal artery stenosis and can predict the beneficial effect of revascularization in some cases.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors , Antihypertensive Agents , Captopril , Hypertension, Renovascular/etiology , Radioisotope Renography , Renal Artery Obstruction/diagnostic imaging , Renal Insufficiency/complications , Adult , Aged , Aged, 80 and over , Female , Glomerular Filtration Rate , Humans , Male , Middle Aged , Predictive Value of Tests , Radiopharmaceuticals , Renal Artery Obstruction/complications , Renal Artery Obstruction/surgery , Sensitivity and Specificity , Technetium Tc 99m Mertiatide
15.
J Infect Dis ; 179(1): 1-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9841815

ABSTRACT

In normal persons, circulating gammadelta T cells comprise a minor cell subset (0.5%-6% of total lymphocytes). gammadelta T cells were studied in the context of therapeutic immunosuppression in transplanted patients. Flow cytometry detected an expansion of gammadelta T cells in 31 of 205 renal allograft recipients and in 2 of 41 uremic patients but in none of 45 healthy subjects. Univariate statistical analysis identified cytomegalovirus (CMV) infection (P<. 001), second graft (P<.001), and antithymocyte globulin treatment (P=.01) as three variables associated with high levels (>=6%) of circulating gammadelta T cells in allograft recipients. Multivariate analysis further indicated that CMV infection was the only independent parameter associated with >6% gammadelta T cells. gammadelta T cell expansion directly followed CMV infection and was never observed in persons who did not develop CMV infection. Thus gammadelta T cells may represent a first-line defense mechanism against CMV infection in a person whose alphabeta T cell response has been weakened by immunosuppression.


Subject(s)
Cytomegalovirus Infections/etiology , Cytomegalovirus Infections/immunology , Kidney Transplantation/adverse effects , Kidney Transplantation/immunology , Opportunistic Infections/etiology , Opportunistic Infections/immunology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocyte Subsets/immunology , Adolescent , Adult , Aged , Antilymphocyte Serum/adverse effects , Case-Control Studies , Cytomegalovirus Infections/blood , Female , Humans , Immunocompromised Host , Lymphocyte Count , Male , Middle Aged , Opportunistic Infections/blood , Prospective Studies , Reoperation , Retrospective Studies , Uremia/blood , Uremia/immunology , Uremia/surgery
16.
AJR Am J Roentgenol ; 171(6): 1611-5, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9843297

ABSTRACT

OBJECTIVE: This study was designed to compare power Doppler images of perfusion with interlobar resistive index measurements obtained during the early monitoring of renal graft transplant to diagnose cortical perfusion abnormalities and assess prognosis. SUBJECTS AND METHODS: Thirty-one patients underwent color Doppler sonography (4-7 MHz and 7-10 MHz) on day 6+/-2 after renal transplantation. Cortical vessel density was assessed visually and classified as either normal or decreased. Twelve months after transplantation, the results of power Doppler imaging and the levels of resistive index were reviewed in light of clinical and laboratory findings, graft biopsy results, and functional outcome. RESULTS: No significant relationship was observed among power Doppler grades, levels of resistive index, and renal function. Power Doppler grades and resistive index levels failed to allow us to distinguish between tubulopathy and rejection. However, we found a statistically significant relationship between renal function at 12 months after transplantation and power Doppler grade (p = .04). CONCLUSION: This study suggests that color Doppler sonography is insensitive in revealing and in allowing radiologists to differentiate the causes of graft dysfunction. However, power Doppler sonography allows a prediction of the functional recovery of the graft at 12 months after transplantation not provided by resistive index levels.


Subject(s)
Kidney Transplantation , Renal Circulation , Ultrasonography, Doppler, Color , Vascular Resistance , Adult , Female , Graft Rejection/diagnostic imaging , Humans , Kidney/physiopathology , Kidney Cortex/blood supply , Kidney Cortex/diagnostic imaging , Kidney Tubular Necrosis, Acute/diagnostic imaging , Male , Middle Aged , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...